151. Microtubule associated protein 2 in bipolar depression: Impact of pregnenolone
- Author
-
E. Sherwood Brown, Alexandra Kulikova, Collette Bice, Jung Min Yon, John Park, Shivani Daftary, Yun-Bae Kim, and Ehn Kyoung Choi
- Subjects
Adult ,Male ,0301 basic medicine ,medicine.medical_specialty ,Bipolar Disorder ,Neuroactive steroid ,Blotting, Western ,Placebo ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Bipolar disorder ,Depression (differential diagnoses) ,Mood Disorders ,medicine.disease ,Antidepressive Agents ,Clinical trial ,Psychiatry and Mental health ,Clinical Psychology ,030104 developmental biology ,Endocrinology ,Mood disorders ,Pregnenolone ,Antidepressant ,Female ,Psychology ,Microtubule-Associated Proteins ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Background Pregnenolone, and related neurosteroids, may have antidepressant properties. Preclinical research proposes that microtubule associated protein 2 (MAP2) binding may be a mechanism for antidepressant properties of pregnenolone. Thus, MAP2 might be a novel target for antidepressant therapy. This clinical study is the first to examine serum MAP2 levels in people with bipolar depression and controls, and whether pregnenolone treatment is associated with a change in MAP2 levels. Methods Blood samples from a previously published clinical trial of pregnenolone for adult bipolar depression were analyzed at baseline and week 6 of treatment with pregnenolone or placebo for serum MAP2 levels using Western Blot. MAP2 levels from healthy controls were also obtained. Results MAP2 levels in the bipolar depressed patients (n=11) tended to be higher than in controls (n=4) (p=0.062). MAP2 levels decreased non-significantly from baseline to week 6 in placebo (n=5) and pregnenolone-treated patients (n=6). MAP2 level changes correlated positively with change in self-reported depressive symptom scores in the pregnenolone group (r=0.771, p=0.072) but not in the placebo group (r=0.000, p=1.000). Limitations This study, exploring relationships between MAP-2 in humans with mood disorders, is limited by the small sample size. Thus, the findings must be viewed with great caution. Conclusion These findings suggest possible differences in serum MAP-2 levels between bipolar depressed persons and controls and a relationship between changes in depressive symptoms and MAP-2 levels during pregnenolone therapy. Findings suggest additional research is needed on MAP-2 in mood disorders.
- Published
- 2017